North China Pharmaceutical Co., Ltd. (600812.SH) announced its wholly-owned subsidiary, Huasheng Company, recently obtained the Certification of Suitability to European Pharmacopoeia (CEP) for Polymyxin B Sulfate active pharmaceutical ingredient (API) from the European Directorate for the Quality of Medicines & HealthCare (EDQM).
Polymyxin B Sulfate treats acute infections caused by Pseudomonas aeruginosa-susceptible strains, serving as the primary medication for urinary tract, meningeal, and bloodstream infections induced by this pathogen. This therapeutic agent is also indicated for severe infections stemming from susceptible strains of Haemophilus influenzae (particularly meningeal infections), Escherichia coli (especially urinary tract infections), Enterobacter aerogenes (notably bacteremia), and Klebsiella pneumoniae (specifically bacteremia) when lower-toxicity alternatives prove ineffective or contraindicated.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.